Exelixis, Inc.
NASDAQ:EXELBiotechnology
+$0.34 today
- Market cap
- $17.17B
- Beta
- 0.43
- P/E (TTM)
- 16.3
- EPS (TTM)
- $3.23
Volume 1.82M
Average 2.55M
EXEL Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Exelixis, Inc.NASDAQ: EXEL
Accounts Receivables · Q2 FY2026 · quarter ended Jul 2026
Accounts receivables turns positive
Q2 FY2026 accounts receivables was $6.73M, compared with -$10.72M a year earlier. Trailing-twelve-month accounts receivables was -$29.86M.
Context
- Accounts receivables amounted to 0.9% of revenue in FY2025, down 0.4 pp from a year earlier.
- Accounts receivables increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly accounts receivables holds near $6.73M or moves back toward the trailing-twelve-month quarterly average of -$7.46M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- (21.4M) USD
- Year-over-year change
- +23.4%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2026-01-02 | (21.4M) | +23.4% |
| FY2024 | 2025-01-03 | (27.95M) | -23.5% |
| FY2023 | 2023-12-31 | (22.62M) | -133.8% |
| FY2022 | 2022-12-31 | 66.85M | +154.6% |
| FY2021 | 2021-12-31 | (122.32M) | — |
Accounts Receivables vs competitors
How EXEL compares with its peers on the latest reported figures
- EXEL's LTM Jul 2026 accounts receivables of $29.86M is the 3rd largest of the 8 companies compared; the peer median is $8.4M.
- Its year-over-year change of -128.6% is the lowest of 5, against a peer median of +102.5%.
- Accounts receivables amounts to 1.2% of revenue for EXEL, versus a peer median of 3.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $282.32M | +167.9% | +81.5% | 4.9% | |
| LTM Jun 2026 | $189.32M | — | -57.2% | 4.6% | |
| LTM Jul 2026 | $29.86M | -128.6% | — | 1.2% | |
| LTM Mar 2026 | $22.74M | +71.8% | +119.7% | 10.5% | |
| LTM Jun 2025 | $9.93M | +133.2% | — | 1.6% | |
| LTM Mar 2026 | $8.4M | -40.2% | -25.8% | 2.8% | |
| LTM Sep 2026 | $0 | — | — | 0.0% | |
| LTM Jun 2026 | $0 | — | — | — | |
| Peer median (excluding EXEL) | $8.4M | +102.5% | +27.8% | 3.7% | |
Competitors are the stored peer set for EXEL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Jan 2025 | FY2025 Jan 2026 |
|---|---|---|---|---|---|
| Net Income | 231.06M | 182.28M | 207.77M | 521.27M | 782.57M |
| Depreciation & Amortization | 13.63M | 20.88M | 25.72M | 28.8M | 29.06M |
| Deferred Income Tax | 46.53M | (60.36M) | (133.21M) | (59.46M) | 126.24M |
| Stock-Based Compensation | 119.82M | 107.57M | 106.35M | 93.84M | 112.98M |
| Change in Working Capital | (39.01M) | (12.8M) | (13.97M) | (13.45M) | (191.2M) |
| Accounts Receivables | (122.32M) | 66.85M | (22.62M) | (27.95M) | (21.4M) |
| Inventory | (13.21M) | (11.68M) | (12.98M) | 5.45M | 12.23M |
| Accounts Payables | 55.09M | 23.36M | 50.11M | (21.89M) | (50.15M) |
| Other Working Capital | 41.43M | (91.32M) | (28.48M) | 30.93M | (131.87M) |
| Other Non-Cash Items | 28.78M | 125.04M | 140.68M | 128.98M | 24.62M |
| Operating Cash Flow | 400.8M | 362.61M | 333.32M | 699.97M | 884.27M |
| Capital Expenditures | (64.23M) | (138.46M) | (162.97M) | (66.19M) | (39.93M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (1.36B) | (1.45B) | (902.47M) | (927.91M) | (632.5M) |
| Sales of Investments | 1.38B | 1.06B | 1.04B | 877.31M | 1.02B |
| Other Investing Activities | (10M) | (110.75M) | (122.5M) | (37.75M) | (31.5M) |
| Investing Cash Flow | (42.88M) | (524.41M) | (26.96M) | (116.78M) | 350.44M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 0 | 23.89M | 33.45M | 61.85M | 49.14M |
| Common Stock Repurchased | 0 | 0 | (550.38M) | (652.03M) | (947.51M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (14.8M) | (23.3M) | (29.12M) | (38.63M) | (71.22M) |
| Financing Cash Flow | (14.8M) | 586K | (546.05M) | (628.81M) | (969.59M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 343.12M | (161.21M) | (239.68M) | (45.62M) | 265.11M |
| Free Cash Flow | 336.58M | 224.16M | 170.36M | 633.79M | 844.34M |
Exelixis, Inc.
NASDAQ:EXEL
Intrinsic Alpha fair value
Locked
Current Price
$68.29
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.